Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: CCR1 receptor antagonists - Ligand

X
Drug Profile

Research programme: CCR1 receptor antagonists - Ligand

Alternative Names: PS 031291; PS 375179

Latest Information Update: 11 Mar 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmacopeia Drug Discovery
  • Developer Ligand Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action CCR1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Cancer
  • Discontinued Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 11 Mar 2011 Ligand's CCR1 receptor antagonists research programme is still available for licensing. www.ligand.com
  • 09 Feb 2009 PS 031291 is available for out-licensing (http://www.pharmacopeia.com)
  • 23 Dec 2008 Pharmacopeia has been acquired by Ligand Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top